- Home
- BLIN vs NRSN Comparison
BLIN vs NRSN Comparison
Compare BLIN & NRSN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BLIN
- NRSN
- Stock Information
- Founded
- BLIN 2000
- NRSN 2017
- Country
- BLIN United States
- NRSN Israel
- Employees
- BLIN N/A
- NRSN N/A
- Industry
- BLIN EDP Services
- NRSN Biotechnology: Pharmaceutical Preparations
- Sector
- BLIN Technology
- NRSN Health Care
- Exchange
- BLIN Nasdaq
- NRSN Nasdaq
- Market Cap
- BLIN 20.6M
- NRSN 17.8M
- IPO Year
- BLIN 2007
- NRSN 2021
- Fundamental
- Price
- BLIN $1.57
- NRSN $1.09
- Analyst Decision
- BLIN Strong Buy
- NRSN Hold
- Analyst Count
- BLIN 1
- NRSN 1
- Target Price
- BLIN $4.62
- NRSN N/A
- AVG Volume (30 Days)
- BLIN 137.4K
- NRSN 159.3K
- Earning Date
- BLIN 02-13-2025
- NRSN 04-04-2025
- Dividend Yield
- BLIN N/A
- NRSN N/A
- EPS Growth
- BLIN N/A
- NRSN N/A
- EPS
- BLIN N/A
- NRSN N/A
- Revenue
- BLIN $15,394,000.00
- NRSN N/A
- Revenue This Year
- BLIN $7.51
- NRSN N/A
- Revenue Next Year
- BLIN $6.57
- NRSN N/A
- P/E Ratio
- BLIN N/A
- NRSN N/A
- Revenue Growth
- BLIN N/A
- NRSN N/A
- 52 Week Low
- BLIN $0.76
- NRSN $0.51
- 52 Week High
- BLIN $2.80
- NRSN $2.33
- Technical
- Relative Strength Index (RSI)
- BLIN 40.34
- NRSN 44.12
- Support Level
- BLIN $1.65
- NRSN $1.12
- Resistance Level
- BLIN $1.83
- NRSN $1.24
- Average True Range (ATR)
- BLIN 0.19
- NRSN 0.08
- MACD
- BLIN -0.05
- NRSN -0.01
- Stochastic Oscillator
- BLIN 5.74
- NRSN 13.57
About BLIN Bridgeline Digital Inc.
Bridgeline Digital Inc is a AI-powered marketing technology company that offers a suite of products that help companies grow online revenue by driving more traffic to their websites, converting more visitors to purchasers, and increasing average order value. Company software is available through a cloud-based Software as a Service (SaaS) model. It helps to maximize the performance of critical websites, intranets, and online stores. The company generates revenue from digital engagement services, subscription, perpetual licenses, maintenance, and hosting. Geographically, it derives a majority of revenue from the United States.
About NRSN NeuroSense Therapeutics Ltd.
NeuroSense Therapeutics Ltd is a clinical-stage biotechnology company focused on discovering and developing treatments for patients suffering from debilitating neurodegenerative diseases, these diseases include Amyotrophic Lateral Sclerosis, or ALS, Alzheimer's disease and Parkinson's disease, among others. Its product candidate, PrimeC, is a novel extended-release, or ER, oral formulation of a fixed dose combination of two generic FDA-approved drugs, ciprofloxacin and celecoxib, combined in a specific ratio.